110 related articles for article (PubMed ID: 24971922)
1. Prolactin levels and gender are associated with tumour behaviour in prolactinomas but Ki-67 index is not.
Cander S; Gül ÖÖ; Ertürk E; Tuncel E; Ersoy C
Endokrynol Pol; 2014; 65(3):210-6. PubMed ID: 24971922
[TBL] [Abstract][Full Text] [Related]
2. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
4. [Expression of galectin-3 in invasive prolactinomas].
Wang H; Wang MD; Ma WB; Yang D; Shi YF; Kong YG; Li SF; Li ZH; Wang RZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):380-1. PubMed ID: 16038281
[TBL] [Abstract][Full Text] [Related]
5. [Prolactinoma in man: clinical and histological characteristics].
Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
[TBL] [Abstract][Full Text] [Related]
6. [Prolactinoma in a child showing high MIB-1 labeling index: a case report].
Akamine S; Miyamoto T; Sugiura Y; Takehara S; Hiramatsu H; Nishizawa S; Yokota N
No Shinkei Geka; 2000 Jun; 28(6):547-53. PubMed ID: 10875113
[TBL] [Abstract][Full Text] [Related]
7. Growth potential of prolactinomas in men: is it really different from women?
Nishioka H; Haraoka J; Akada K
Surg Neurol; 2003 May; 59(5):386-90; discussion 390-1. PubMed ID: 12765811
[TBL] [Abstract][Full Text] [Related]
8. Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance.
Jiang M; Mou CZ; Han T; Wang M; Yang W
J Int Med Res; 2012; 40(4):1284-94. PubMed ID: 22971480
[TBL] [Abstract][Full Text] [Related]
9. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.
Zielinski G; Ozdarski M; Maksymowicz M; Szamotulska K; Witek P
Front Endocrinol (Lausanne); 2020; 11():439. PubMed ID: 32733387
[No Abstract] [Full Text] [Related]
10. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.
Delgrange E; Trouillas J; Maiter D; Donckier J; Tourniaire J
J Clin Endocrinol Metab; 1997 Jul; 82(7):2102-7. PubMed ID: 9215279
[TBL] [Abstract][Full Text] [Related]
11. The role of Ki-67 in women with a resistant prolactinoma: a retrospective analysis in 199 hospitalized patients over a period of 5 years.
Lu C; Ren Z; Huan C; Cui G
Pak J Pharm Sci; 2014 Jul; 27(4 Suppl):1075-81. PubMed ID: 25016269
[TBL] [Abstract][Full Text] [Related]
12. Prolactinomas in male and female patients: a comparative clinicopathologic study.
Calle-Rodrigue RD; Giannini C; Scheithauer BW; Lloyd RV; Wollan PC; Kovacs KT; Stefaneanu L; Ebright AB; Abboud CF; Davis DH
Mayo Clin Proc; 1998 Nov; 73(11):1046-52. PubMed ID: 9818037
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas.
Xie W; Liu C; Wu D; Li Z; Li C; Zhang Y
Oncotarget; 2016 Aug; 7(32):50883-50894. PubMed ID: 27438154
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 and Clinical Correlations in Patients with Resistant Prolactinomas.
Lu C; Liu Y; Lu Z; Huan C
Ann Clin Lab Sci; 2020 Mar; 50(2):199-204. PubMed ID: 32366557
[TBL] [Abstract][Full Text] [Related]
15. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
16. Gender-related differences in prolactin secretion in pituitary prolactinomas.
Nishioka H; Haraoka J; Akada K; Azuma S
Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptors in prolactinomas: a clinico-pathological study.
Kaptain GJ; Simmons NE; Alden TD; Lopes MB; Vance ML; Laws ER
Pituitary; 1999; 1(2):91-8. PubMed ID: 11081186
[TBL] [Abstract][Full Text] [Related]
18. Prolactin secreting pituitary carcinoma.
Petterson T; MacFarlane IA; MacKenzie JM; Shaw MD
J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1205-6. PubMed ID: 1479402
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.
Raverot G; Wierinckx A; Dantony E; Auger C; Chapas G; Villeneuve L; Brue T; Figarella-Branger D; Roy P; Jouanneau E; Jan M; Lachuer J; Trouillas J;
J Clin Endocrinol Metab; 2010 Apr; 95(4):1708-16. PubMed ID: 20164287
[TBL] [Abstract][Full Text] [Related]
20. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
